Emricasan™, a caspase inhibitor for liver diseases
The founding team of Conatus re-acquired Emricasan™, a caspase inhibitor for reducing apoptosis and inflammation in the treatment of liver diseases. Emricasan™ is a hepatoprotectant arresting the rate of deterioration of liver function. It is in several Phase II clinical studies for a number of liver diseases.
CEO Steven J. Mento